Cytomed TherapeuticsGDTC
13F holders, Q3 2024 (September 30)1holders
1new positions
0sold out
$1.57avg. 13F price*
At the end of Q3 2024, 1 institutions reported holding Cytomed Therapeutics Ltd. (GDTC) in their 13F filings, unchanged from Q1 2024. 1 opened new positions and 0 sold out. The largest holder was UBS Group AG ($96).
- Company
- Cytomed Therapeutics Ltd.
- CUSIP
- Y1R80M106
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $96 |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q3 2024: 61 shares bought, net +61 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| UBS Group AG | 0.00% | New | 61 | $96 |
"% of holder's portfolio" is GDTC's weight in each manager's 13F, not the share of Cytomed Therapeutics Ltd. the manager owns.